ALK gene rearrangements are detectable in approximately 3% to 5% of patients with NSCLC.1, 2, 3 Treatment with ALK inhibitors is the preferred initial systemic approach for ALK rearrangement-positive (ALK+) metastatic NSCLC.4 This evidence concerns the gene ALK and non-small cell lung carcinoma.